Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
The current COO will assume leadership of the neuro-focused pharma firm while the company board investigates questions on Leen Kawas’s doctoral research.
By Melanie Brickman Borchard, PhD, MSc, director of life sciences, New York Academy of Sciences
Increased access to real-world data sources opens up new possibilities, but it also raises new ethical questions, which cannot be tackled by one organization, government agency, or company alone.